Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can 'Zombie Cell' cleaners help frail cancer survivors walk faster?

NCT ID NCT04733534

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two short-term drug regimens—dasatinib plus quercetin, or fisetin alone—in 110 adult survivors of childhood cancer who are frail. The goal is to see if these 'senolytic' drugs can clear aging cells, improve walking speed, and reduce frailty. It is a first-of-its-kind pilot study, so results will guide future larger trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dasatinib plus Quercetin, or Fisetin alone
What this could lead to
If successful, this could point toward a treatment that reduces frailty and improves physical function in adult survivors of childhood cancer.
What could go wrong
This is a small, early-phase pilot study without a placebo group, so results may not be definitive. The drugs may cause side effects or fail to improve frailty.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

110 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant in SJLIFE and \> 5 years from diagnosis. * ≥18 years of age. * Frail (2 of 4 objectively measured Fried criteria adapted,(excluding self-reported fatigue as a criteria), including abnormal walking speed; muscle strength; activity level; and muscle mass). See Section 5 for details. * CD3+ T lymphocytes: p16INK4A detected at \<34 cycles by RT PCR. * Agrees to use contraception as Dasatinib is teratogenic. * Female participant has a negative pregnancy test. * QTc \<450 milliseconds in electrocardiogram. * Able to take oral medications. Exclusion Criteria: * Currently has HIV, Hepatitis B/C, invasive fungal infection * Anemia or as per clinical judgement. * Hypersensitivity to study drugs * New/active malignancy/taking chemotherapy and/or radiation except non-melanoma skin cancers * Currently taking medications that inhibit or induce CYP3A4 or that are sensitive to substrates or substrates with a narrow therapeutic range for CYP2C8, CYP2C9, or CYP2D6. * Taking anticoagulants or antimicrobial agents * Currently taking Quercetin or Fisetin * Pregnant or nursing at time of enrollment/during the study * Impaired cognition or motor performance due to congenital defects * Currently participating in another research intervention to aid walking speed or other measures of frailty including muscle strength; low activity; muscle mass or exhaustion/fatigue * Participant is a Non-English Speaker * Uncontrolled pleural/pericardial effusion or ascites * Subjects on anticoagulant or antiplatelet agents (Warfarin, Clopidogrel \[Plavix\]; Dipyridamole + Aspirin \[Aggrenox\]; Ticagrelor \[Brilintal\]; Prasugrel \[Effient\]; Ticlopidine \[Ticlid\]; or other) who are unable or unwilling to reduce or hold therapy prior to and during the 2-3 day drug dosing. Subjects may continue their previous regimen after drug dosing is complete. * Cognitive impairment defined by IQ \<80 * Diagnosis of a psychotic disorder * Laboratory tests as indicated or as per clinical judgement * Severe hepatic dysfunction with ALT/AST \> 3 times upper limit of normal. * Total bilirubin \> 2 times upper limit of normal. * eGFR \<25 ml/min/1.73m2 or as per clinical judgement. * Hemoglobin \< 7 g/dl; white blood cell count ≤2,000/mm3 (≤2.0 x 109/L) or ≥20,000/mm3 (≥20 x 109/L); platelet count ≤40,000/μL (≤40 x 109/L); absolute neutrophil count ≤1 x 109/L; lymphocyte count \<0.3 x 109/L at screening as a marker of poor nutrition * Fasting glucose \>300. * Participant is unable to ambulate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.